---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-014674"
form_type: "8-K"
ticker: "IRD"
cik: "0001228627"
company_name: "Opus Genetics, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T08:57:54.948520+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ocuphire Pharma reports Q4 2022 net income $33.9M, full-year net income $17.9M; cash $42.6M

## Summary
- Net income $17.9M for 2022 vs net loss $56.7M in 2021; diluted EPS $0.87.
- Revenue $39.9M from Nyxol license agreement with Viatris (upfront $35M).
- Cash $42.6M, no debt, runway into 2025.
- PDUFA date Sept 28, 2023 for Nyxol in reversal of mydriasis; $10M milestone upon approval.
- APX3330 ZETA-1 trial achieved statistical significance on key endpoint; End-of-Phase 2 meeting planned.

## SEC filing metadata
- accession: 0001140361-23-014674
- form_type: 8-K
- ticker: IRD
- cik: 0001228627
- company_name: Opus Genetics, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/0001140361-23-014674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/brhc10050620_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-014674
- JSON: https://secwatch.observer/filing/0001140361-23-014674.json
- Plain text: https://secwatch.observer/filing/0001140361-23-014674.txt

## Key facts
- Earnings Releases
  Opus Genetics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/0001140361-23-014674-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.